Table 1.
Descriptive summary and univariate analysis
| All patients (n = 519) | Remission of diabetes | P value | ||
|---|---|---|---|---|
| No (n = 264) | Yes (n = 255) | |||
| Sex | 0.035 | |||
| Female | 348 (67.1) | 165 (62.5) | 183 (71.8) | |
| Male | 171 (32.9) | 99 (37.5) | 72 (28.2) | |
| Age at time of surgery (years) | 52 (45; 58) | 54 (47; 60) | 50 (42; 55) | <0.001 |
| BMI before surgery (kg/m2) | 45.2 (40.3; 50.6) | 43.9 (39.1; 49.2) | 46.2 (41.3; 52.0) | <0.001 |
| Duration of diabetes (years) | 6.0 (2.5; 11.0) | 10.0 (6.0; 15.0) | 3.0 (1.00; 6.00) | <0.001 |
| Preoperative insulin use | <0.001 | |||
| No | 331 (63.8) | 111 (42.0) | 220 (86.3) | |
| Yes | 188 (36.2) | 153 (58.0) | 35 (13.7) | |
| Diabetes medications | 2.0 (1.0; 3.0) | 2.0 (2.0; 3.0) | 1.0 (1.0; 2.0) | <0.001 |
| Preoperative HbA1c | <0.001 | |||
| % | 7.3 (6.4; 8.5) | 7.9 (7.0; 9.2) | 6.7 (6.0; 7.7) | |
| mmol/mol | 56 (46; 69) | 63 (53; 77) | 50 (42; 61) | |
| Poor glycemic control (HbA1c ≥7%) | <0.001 | |||
| No | 215 (41.4) | 68 (25.8) | 148 (58.0) | |
| Yes | 304 (58.6) | 196 (74.2) | 107 (42.0) | |
| Liver steatosis score | 0.079 | |||
| 0 | 112 (21.6) | 68 (25.8) | 44 (17.3) | |
| 1 | 272 (52.4) | 136 (51.5) | 136 (53.3) | |
| 2 | 107 (20.6) | 48 (18.2) | 59 (23.1) | |
| 3 | 28 (5.4) | 12 (4.5) | 16 (6.3) | |
| Lobular inflammation score | 0.128 | |||
| 0 | 160 (31.2) | 80 (30.3) | 80 (31.4) | |
| 1 | 254 (48.9) | 140 (53.0) | 114 (44.7) | |
| 2 | 99 (18.8) | 41 (15.5) | 58 (22.7) | |
| 3 | 6 (1.14) | 3 (1.1) | 3 (1.2) | |
| Hepatocyte ballooning score | 0.539 | |||
| 0 | 335 (64.5) | 165 (62.5) | 170 (66.7) | |
| 1 | 159 (30.6) | 84 (31.8) | 75 (29.4) | |
| 2 | 25 (4.8) | 15 (5.7) | 10 (3.9) | |
| Liver fibrosis score | 0.145 | |||
| 0 | 308 (59.3) | 156 (59.1) | 152 (59.6) | |
| 1 | 107 (20.6) | 56 (21.2) | 51 (20.0) | |
| 2 | 48 (9.2) | 19 (7.2) | 29 (11.4) | |
| 3 | 42 (8.1) | 22 (8.3) | 20 (7.8) | |
| 4 | 14 (2.7) | 11 (4.2) | 3 (1.2) | |
Data are n (%) or median (interquartile range). Liver histology was scored according to the NASH Clinical Research Network definitions (9). Significant P values (P < 0.05) are presented in bold.